Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A new form of therapy may halt or even reverse a form of progressive vision loss, spinocerebellar ataxia type 7 (SCA7). This new therapy has the potential to treat neurogenetic diseases effectively and with far fewer side effects than other medications.
Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of macular edema in patients with noninfectious uveitis.
During aging, loss of vision and cognition often coincide. In a new study, researchers funded by the National Eye Institute (NEI) and the National Institute on Aging (NIA) have found that vision loss precedes loss of mental capacity.
Vision researcher, T. Michael Redmond, Ph.D., chief of the National Eye Institute (NEI) Laboratory of Retinal Cell and Molecular Biology, is a recipient of the 2018 António Champalimaud Vision Award for foundational science discoveries about the molecular
Scientists funded by the National Eye Institute (NEI) report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP).